Israel China Biotechnology (ICB) Ltd (ICB) — Financial Flexibility Index
Israel China Biotechnology (ICB) Ltd (ICB) has a Financial Flexibility Index of -0.26x as of June 2021. Free cash flow of ILA-1.06 Million (operating CF ILA-1.06 Million minus capex ILA0.00) represents 0% of total liabilities (ILA4.11 Million). Check how tangible is Israel China Biotechnology (ICB) Ltd's equity to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Israel China Biotechnology (ICB) Ltd Financial Flexibility Index (2015–2020)
Historical Financial Flexibility Index trend for Israel China Biotechnology (ICB) Ltd across 6 annual periods. For the full cash flow conversion analysis, see ICB operating cash flow.
Annual Financial Flexibility Index for Israel China Biotechnology (ICB) Ltd (2015–2020)
Year-by-year free cash flow to debt coverage for Israel China Biotechnology (ICB) Ltd. Explore how well can Israel China Biotechnology (ICB) Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (ILA) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2020 | -0.55x | ILA-4.33 Million | ILA-4.34 Million | ILA7.87 Million | ▼ -26.2% |
| 2019 | -0.44x | ILA-4.22 Million | ILA-4.22 Million | ILA9.68 Million | ▲ +75.8% |
| 2018 | -1.80x | ILA-4.43 Million | ILA-4.75 Million | ILA2.46 Million | ▼ -81.1% |
| 2017 | -0.99x | ILA-2.85 Million | ILA-3.17 Million | ILA2.87 Million | ▲ +45.7% |
| 2016 | -1.83x | ILA-3.94 Million | ILA-3.94 Million | ILA2.15 Million | ▼ -16.3% |
| 2015 | -1.58x | ILA-3.77 Million | ILA-3.81 Million | ILA2.39 Million | — |